Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $2.2 million.

  • Tango Therapeutics' Accounts Payables fell 4579.28% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 4579.28%. This contributed to the annual value of $1.6 million for FY2024, which is 4251.35% down from last year.
  • Per Tango Therapeutics' latest filing, its Accounts Payables stood at $2.2 million for Q3 2025, which was down 4579.28% from $2.6 million recorded in Q2 2025.
  • Tango Therapeutics' Accounts Payables' 5-year high stood at $6.3 million during Q3 2022, with a 5-year trough of $26279.0 in Q2 2021.
  • Moreover, its 5-year median value for Accounts Payables was $3.1 million (2021), whereas its average is $3.0 million.
  • Per our database at Business Quant, Tango Therapeutics' Accounts Payables skyrocketed by 6009361.08% in 2021 and then crashed by 7784.27% in 2024.
  • Tango Therapeutics' Accounts Payables (Quarter) stood at $3.2 million in 2021, then surged by 38.03% to $4.5 million in 2022, then plummeted by 37.46% to $2.8 million in 2023, then crashed by 42.51% to $1.6 million in 2024, then skyrocketed by 39.23% to $2.2 million in 2025.
  • Its Accounts Payables was $2.2 million in Q3 2025, compared to $2.6 million in Q2 2025 and $3.2 million in Q1 2025.